Speirs Toby Peter, Tuffin Nicole, Mundy-Baird Finlay, Sakota Helena, Mulholland Sarah, Westlake Michelle, Lyon Max, Medford Andrew R, Sharp Charles, Darby Michael, Albur Mahableshwar, Keeley Francis, Burden Helena, Kenward Charlie, Jonas Elizabeth, Barratt Shaney, Adamali Huzaifa I
Bristol Interstitial Lung Disease Service, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
Department of Radiology, North Bristol NHS Trust, Bristol, UK.
BJGP Open. 2021 Dec 14;5(6). doi: 10.3399/BJGPO.2021.0083. Print 2021.
Long-term nitrofurantoin (NF) treatment can result in pulmonary and hepatic injury. Current guidelines do not outline the type or frequency of monitoring required for detection of these injuries.
To assess 1) awareness of NF complications among prescribers; 2) monitoring practice; and 3) to describe the pulmonary sequelae of NF-related complications.
DESIGN & SETTING: Evaluation of prescribing habits by questionnaires and review of GP databases, and case-note review in secondary care.
The following study procedures were undertaken: 1) an electronic questionnaire was distributed to prescribers, interrogating prescribing and monitoring practices, and awareness of complications; 2) an analysis was undertaken (June-July 2020) of NF monitoring among GPs in the local clinical commissioning group (CCG); and 3) a case review was carried out of patients diagnosed with NF-induced interstitial lung disease (NFILD) at the interstitial lung disease (ILD) centre (2014-2020).
A total of 125 prescribers of long-term NF responded to the questionnaire (82.4% GPs; 12.0% urologists). Many were unaware of the potential for liver (42.4%) and lung (28.0%) complications; 40.8% and 52.8% never monitored for these, respectively. Only 53.3% of urologists believed themselves responsible for arranging monitoring, while nearly all GPs believed this to be the prescriber's responsibility (94.2%). One-third of all responders considered current () guidelines 'not at all sufficient/clear', with mean clarity scoring of 2.2/5. Among patients with NFILD ( = 46), NF had been prescribed most often (69.6%) for treatment of recurrent UTI and 58.6% ( = 27) were prescribed for >6 months. On withdrawal of the medication 61.4% displayed resolution (completely or minimal fibrosis), while 15.9% of patients had progressive lung fibrosis.
NF can cause marked or irreversible lung complications and there is currently a shortfall in awareness and monitoring. Existing monitoring guidelines should be augmented.
长期服用呋喃妥因(NF)可导致肺部和肝脏损伤。目前的指南未明确检测这些损伤所需的监测类型或频率。
评估1)开处方者对NF并发症的认知;2)监测实践;3)描述NF相关并发症的肺部后遗症。
通过问卷调查评估处方习惯,回顾全科医生数据库,并在二级医疗中进行病例记录回顾。
采用以下研究程序:1)向开处方者发放电子问卷,询问处方和监测实践以及对并发症的认知;2)(2020年6月至7月)对当地临床委托小组(CCG)的全科医生进行NF监测分析;3)对间质肺病(ILD)中心(2014 - 2020年)诊断为NF诱导的间质性肺病(NFILD)的患者进行病例回顾。
共有125名长期开具NF处方的医生回复了问卷(82.4%为全科医生;12.0%为泌尿科医生)。许多人未意识到肝脏(42.4%)和肺部(28.0%)并发症的可能性;分别有40.8%和52.8%的人从未对这些进行监测。只有53.3%的泌尿科医生认为自己有责任安排监测,而几乎所有全科医生都认为这是开处方者的责任(94.2%)。所有回复者中有三分之一认为当前()指南“完全不够/不清晰”,平均清晰度评分为2.2/5。在NFILD患者(n = 46)中,NF最常用于治疗复发性尿路感染(69.6%),58.6%(n = 27)的患者用药超过6个月。停药后,61.4%的患者病情缓解(完全或仅有轻微纤维化),而15.9%的患者出现进行性肺纤维化。
NF可导致明显或不可逆的肺部并发症,目前在认知和监测方面存在不足。应加强现有的监测指南。